Study guide
Communicating Intensity (THR, RPE, talk test), Monitoring & Modifying the Prescription
ACSM Certified Clinical Exercise Physiologist ACSM-CEP
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 The ACSM-CEP Role, Job Definition & Scope of Practice 1.2 Exam Format, Domain Weights & Scoring 1.3 Eligibility, Study Planning & Test-Day Strategy
2 Applied Exercise Physiology & Metabolic Calculations
Bioenergetics & Energy Systems (ATP-PC, glycolytic, oxidative) Acute Cardiorespiratory & Metabolic Responses to Aerobic Exercise Responses to Resistance Exercise & Chronic Training Adaptations ACSM Metabolic Equations, METs & Interpreting VO₂ / RER / Ventilatory Threshold
3 Pathophysiology of Clinical Populations
3.1 Coronary Artery Disease, Myocardial Infarction & Revascularization (PCI/CABG) 3.2 Heart Failure, Valvular Disease & Cardiac Rhythm Disorders 3.3 Hypertension, Dyslipidemia & Peripheral Artery Disease 3.4 Pulmonary Disease: COPD, Asthma & Restrictive/Interstitial Disorders 3.5 Diabetes, Metabolic Syndrome & Obesity 3.6 Renal Disease & Musculoskeletal/Orthopedic Conditions 3.7 Neuromuscular, Neurological & Cognitive Conditions (stroke, MS, Parkinson's, SCI) 3.8 Neoplastic, Immunologic & Hematologic Disorders (cancer, HIV/AIDS, anemia)
4 Clinical ECG Interpretation
4.1 ECG Leads, Waveforms, Rate & Rhythm Determination 4.2 Arrhythmias & Conduction Blocks 4.3 Ischemia, Injury & Infarction (ST changes, exercise-induced) 4.4 Drug & Electrolyte ECG Effects; Resting/Exercise Monitoring Setup & Lead Placement
5 Pharmacology for the Clinical Exercise Physiologist
5.1 Beta-Blockers, Calcium-Channel Blockers & Nitrates 5.2 RAAS Agents, Diuretics, Antiarrhythmics, Lipid-Lowering & Antithrombotic Drugs 5.3 Bronchodilators, Corticosteroids, Insulin & Oral Antidiabetic Agents 5.4 Medication Effects on HR/BP & Exercise Response; Dose/Meal/Dialysis Timing
6 Patient Assessment (Domain I, 18%)
6.1 Medical Records, HIPAA/HITRUST, Charting & Physician Referral 6.2 Patient Interview, Medical History & Medication Reconciliation 6.3 Resting Vital Signs, Body Composition & Resting ECG 6.4 Preparticipation Health Screening & Level of Monitoring (PAR-Q+, ACSM algorithm, ACC/AHA · GOLD · ADA · AACVPR) 6.5 Assessing Patient Goals, Readiness & Psychosocial Status
7 Clinical Exercise Testing (Domain II, 18%)
Submaximal Aerobic Tests (treadmill, cycle, step, 6-minute walk) Musculoskeletal Fitness, Mobility & Balance Testing Maximal Symptom-Limited GXT: Protocols, Contraindications & ECG Prep Test Termination: Relative & Absolute Indications Interpreting & Reporting Results (ECG response, RPP, claudication, Duke Treadmill Score, VO₂/RER/AT)
8 Exercise Prescription for Clinical Populations (Domain III, 22%)
FITT-VP Principles, Progression & Prescription Foundations Ex Rx for Cardiovascular Disease (CAD, HF, HTN, PAD, post-revascularization) Ex Rx for Pulmonary Disease (COPD, asthma; breathing techniques, supplemental O2) Ex Rx for Diabetes, Metabolic Syndrome & Obesity Ex Rx for Musculoskeletal, Neuromuscular, Neoplastic & Other Conditions Communicating Intensity (THR, RPE, talk test), Monitoring & Modifying the Prescription
9 Exercise Training & Leadership (Domain IV, 24%)
9.1 Discussing the Training Plan, Clinician & Patient Expectations/Goals 9.2 Instructing & Modifying Exercise Modes (cardiorespiratory, strength/endurance, flexibility, coordination, agility) 9.3 Patient Monitoring & Supervision During Exercise (telemetry, oximetry, glucometry, ECG) 9.4 Contraindications to Training & Modifying Recommendations 9.5 Documenting Clinical Status, Reporting Adverse Events & Interdisciplinary Coordination
10 Education & Behavior Change (Domain V, 13%)
10.1 Behavioral-Health Screening & Recognizing Distress (PHQ-9, Beck, SF-36; referral) 10.2 Patient Education, Health Literacy & Disease Self-Management 10.3 Motivational Interviewing & Behavior-Change Theories (Transtheoretical, HBM, Social Cognitive, Five-A's) 10.4 Promoting Adherence, Self-Efficacy, Relapse Prevention & Social Support
11 Legal, Professional & Emergency Management (Domain VI, 5%)
11.1 Emergency Equipment, Crash Cart Inspection & Emergency Procedures 11.2 CPR/AED/BLS/ACLS, Universal Precautions & EMS Activation 11.3 Scope of Practice, Legal/Ethical Standards, Liability/Negligence, Informed Consent & Professional Organizations (ACSM/AACVPR/AHA)
Communicating Intensity (THR, RPE, talk test), Monitoring & Modifying the Prescription
Key Takeaways Explain This Topic AI
Patients are taught three intensity tools they can use independently: target heart rate range, RPE (Borg 6-20 or CR10), and the talk test, each anchored during a supervised warm-up.
Every prescription includes explicit stop criteria (chest pain, sudden dyspnea, dizziness, irregular heartbeat) with instructions to stop and notify the provider or call EMS.
Supervised sessions monitor HR, BP pre/post exertion, RPE, SpO2 (pulmonary), and glucometry (diabetes), plus non-instrumented signs like pallor, diaphoresis, and gait changes.
Exertional hypotension (a drop in systolic BP as workload increases) is a red flag requiring immediate termination and physician notification.
A falling RPE at the same workload signals a training adaptation and justifies progressing FITT-VP; new symptom-limitation below the prior intensity signals the need to scale back and reassess clinical status.
Last updated: July 2026
Communicating Intensity to the Patient
A written or verbal prescription is only useful if the patient can apply it independently between supervised sessions. The CEP teaches three complementary intensity tools:
Target Heart Rate (THR) range — explained in plain terms (e.g., "keep your pulse between 100 and 115 beats per minute"), calculated from the Karvonen or %HRmax method described in Section 8.1.
Rating of Perceived Exertion (RPE) — the Borg 6–20 scale or the 0–10 category-ratio (CR10) scale. Patients are anchored to the scale by practicing it during a warm-up bout with the CEP present, so their self-rating during independent exercise is calibrated against a known reference.
Talk test — a positive talk test (patient can talk in sentences but not sing) corresponds to roughly moderate intensity; a negative talk test (patient is noticeably breathless and cannot maintain a conversation) corresponds to vigorous intensity. It requires no equipment, which makes it especially useful for home and community settings.
- Tool Moderate intensity Vigorous intensity
- RPE (Borg 6–20) 12–13 14–16
- Talk test Positive (can talk, not sing) Negative (cannot converse comfortably)
- %HRR / %VO2R 40–59% 60–89%
The full written prescription also documents warm-up and cool-down instructions, equipment use, and clear stop criteria and warning signs — chest pain or pressure, unusual or sudden shortness of breath, dizziness/lightheadedness, or an irregular or racing heartbeat — with explicit instructions to stop exercise, and to notify the care team or call emergency services if the symptom is severe or does not resolve with rest.
Equipment Instruction and Adverse-Reaction Reporting
Patients are instructed on correct use of any prescribed home equipment and on wearable fitness technology (heart-rate monitors, activity trackers, continuous glucose monitors) that supports self-monitoring between visits. Instruction includes exactly what to do and whom to contact if an adverse reaction or unexpected symptom occurs during a home or community session, closing the loop between the clinical program and independent exercise. For higher-risk patients (recent MI, unstable arrhythmia, poorly controlled diabetes), the CEP typically provides a written action card listing the specific stop criteria for that patient, the phone number for the clinical program, and clear guidance on when a symptom warrants a call to the care team versus activating emergency medical services — the distinction between "call the clinic tomorrow" and "call 911 now" should never be left for the patient to infer in the moment.
Monitoring During Supervised Sessions
Supervised sessions combine several monitoring streams appropriate to the patient's condition: heart rate (palpation, monitor, or telemetry), blood pressure before and immediately after exertion (especially important in hypertension and CAD), RPE checks at regular intervals, pulse oximetry in pulmonary patients, and glucometry in patients with diabetes. The CEP also watches for non-instrumented signs of intolerance — pallor, diaphoresis, ataxic gait, facial grimacing, or new claudication — any of which can signal a problem before it shows up on a monitor.
Evaluating and Modifying the Prescription
The prescription is not static; it is re-evaluated against three inputs:
Compliance/adherence — missed sessions and the specific barriers behind them (scheduling, transportation, symptoms, motivation) are addressed directly rather than simply re-issuing the same plan.
Signs and symptoms during exercise — an abnormal hemodynamic response requires stopping and escalating. Exertional hypotension (a drop in systolic BP as workload increases) is a red flag requiring immediate session termination and physician notification, as are a hypertensive response (commonly cited around ≥250/115 mmHg), new arrhythmia, angina, or disproportionate dyspnea. These are the same relative and absolute termination indications introduced for maximal graded exercise testing in Chapter 7 — the CEP applies that same judgment continuously during training sessions, not only during a formal test.
Physiologic response over time — if RPE at a given workload has decreased across sessions, that is evidence of a genuine training adaptation, and the FITT-VP prescription should be progressed to maintain an adequate stimulus. Conversely, if the patient now reaches symptom limits below the previously prescribed intensity, the prescription is scaled back and the case is reviewed for a possible change in clinical status requiring medical consultation.
Every session's response — vitals, RPE, symptoms, and any modification made — is documented in the medical record and communicated to the referring provider according to program protocol, with immediate notification for any new or worsening symptom. This documentation and communication loop is what allows Domain IV (Exercise Training and Leadership) to build safely on the prescription set in Domain III.